TY - JOUR
T1 - Sex-related differences in the association between septal wall thickness and survival
AU - Khoury, Shafik
AU - Zornitzki, Lior
AU - Laufer-Perl, Michal
AU - Bhatia, Raghav T.
AU - Marwaha, Sarandeep
AU - Tome, Maite
AU - Granot, Yoav
AU - Gvili Perelman, Moran
AU - Avivi, Ido
AU - Shacham, Yacov
AU - Szekely, Yishay
AU - Banai, Shmuel
AU - Hochstadt, Aviram
AU - Flint, Nir
AU - Topilsky, Yan
N1 - Publisher Copyright:
© 2024 The Author(s)
PY - 2024/8
Y1 - 2024/8
N2 - Background: In many conditions characterised by septal hypertrophy, females have been shown to have worse outcomes compared to males. In clinical practice and research, similar cutoff points for septal hypertrophy are still used for both sexes. Here, we explore the association between different cutoff points for septal hypertrophy and survival in relation to sex. Methods and results: We performed a retrospective analysis of consecutive patients undergoing echocardiography between March 2010 and February 2021 in a large tertiary referral centre. A total of 70,965 individuals were included. Over a mean follow-up period of 59.1 ± 37 months, 9631 (25 %) males and 8429 (26 %) females died. When the same cutoff point for septal hypertrophy was used for both sexes, females had worse prognosis than males. The impact of septal hypotrophy on survival became statistically significant at a lower threshold in females compared to males: 11.1 mm (HR 1.13, CI 95 %:1.03–1.23, p = 0.01) vs 13.1 mm (HR 1.21, CI 95 %: 1.12–1.32, p < 0.001). However, when indexed wall thickness was used, the cutoff points were 6 mm/body surface area (BSA) (HR 1.08, CI 95 %: 1–1.18, p = 0.04) and 6.2 mm/BSA (HR 1.07, CI 95 %: 1–1.15, p = 0.05) for females and males, respectively. Conclusions: Septal hypertrophy is associated with increased mortality at a lower threshold in females than in males. This may account for the worse prognosis reported in females in many conditions characterised by septal hypertrophy. Applying a lower absolute value or using indexed measurements may facilitate early diagnosis and improve prognostication in females.
AB - Background: In many conditions characterised by septal hypertrophy, females have been shown to have worse outcomes compared to males. In clinical practice and research, similar cutoff points for septal hypertrophy are still used for both sexes. Here, we explore the association between different cutoff points for septal hypertrophy and survival in relation to sex. Methods and results: We performed a retrospective analysis of consecutive patients undergoing echocardiography between March 2010 and February 2021 in a large tertiary referral centre. A total of 70,965 individuals were included. Over a mean follow-up period of 59.1 ± 37 months, 9631 (25 %) males and 8429 (26 %) females died. When the same cutoff point for septal hypertrophy was used for both sexes, females had worse prognosis than males. The impact of septal hypotrophy on survival became statistically significant at a lower threshold in females compared to males: 11.1 mm (HR 1.13, CI 95 %:1.03–1.23, p = 0.01) vs 13.1 mm (HR 1.21, CI 95 %: 1.12–1.32, p < 0.001). However, when indexed wall thickness was used, the cutoff points were 6 mm/body surface area (BSA) (HR 1.08, CI 95 %: 1–1.18, p = 0.04) and 6.2 mm/BSA (HR 1.07, CI 95 %: 1–1.15, p = 0.05) for females and males, respectively. Conclusions: Septal hypertrophy is associated with increased mortality at a lower threshold in females than in males. This may account for the worse prognosis reported in females in many conditions characterised by septal hypertrophy. Applying a lower absolute value or using indexed measurements may facilitate early diagnosis and improve prognostication in females.
KW - Hypertrophic cardiomyopathy
KW - Septal hypertrophy
KW - Sex-related differences
UR - http://www.scopus.com/inward/record.url?scp=85194063739&partnerID=8YFLogxK
U2 - 10.1016/j.ijcha.2024.101427
DO - 10.1016/j.ijcha.2024.101427
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 38846157
AN - SCOPUS:85194063739
SN - 2352-9067
VL - 53
JO - IJC Heart and Vasculature
JF - IJC Heart and Vasculature
M1 - 101427
ER -